We are live on
!
Find out more
CA
CHI Advisors Portfolio holdings
AUM
$252M
1-Year Est. Return
56.99%
This Fund
S&P 500
This Quarter
Est. Return
+14.4%
1 Year Est. Return
+56.99%
3 Year Est. Return
+88.23%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$330M
AUM Growth
-$47.1M
(-13%)
Cap. Flow
-$63.2M
Cap. Flow
% of AUM
-19.18%
Top 10 Holdings %
Top 10 Hldgs %
86.17%
Holding
32
New
8
Increased
6
Reduced
8
Closed
6
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
SLRN
ACELYRIN
SLRN
|
+$54.5M |
| 2 |
Keros Therapeutics
KROS
|
+$6.18M |
| 3 |
Direxion Daily S&P Biotech Bear 3X ETF
LABD
|
+$4.85M |
| 4 |
Disc Medicine
IRON
|
+$4.44M |
| 5 |
Ultragenyx Pharmaceutical
RARE
|
+$3.94M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
RXDX
Prometheus Biosciences, Inc. Common Stock
RXDX
|
+$100M |
| 2 |
VECT
VectivBio Holding AG Ordinary Shares
VECT
|
+$32.5M |
| 3 |
Corvus Pharmaceuticals
CRVS
|
+$4.44M |
| 4 |
KDNY
Chinook Therapeutics, Inc. Common Stock
KDNY
|
+$3.13M |
| 5 |
KZR
Kezar Life Sciences
KZR
|
+$2.16M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 98.53% |
| 2 | Miscellaneous | 1.47% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
Pliant Therapeutics
PLRX
$71.2M
| $56.5M | 17.14% |
3,117,017
+115,182
| +4% | +$2.73M |
|
|
SLRN
2
DELISTED
ACELYRIN
SLRN
| $55.7M | 16.89% |
+2,663,806
| New | +$54.5M |
|
|
VECT
3
DELISTED
VectivBio Holding AG Ordinary Shares
VECT
| $46.9M | 14.24% |
2,782,756
-2,472,728
| -47% | -$32.5M |
|
4
Cullinan Oncology
CGEM
$1.45B
| $36.7M | 11.15% |
3,414,189
+64,729
| +2% | +$688K |
|
|
RPTX
5
DELISTED
Repare Therapeutics
RPTX
| $31.7M | 9.63% |
2,998,734
+795
| +0% | +$8.19K |
|
|
6
Keros Therapeutics
KROS
$223M
| $16.2M | 4.9% |
402,118
+141,059
| +54% | +$6.18M |
|
|
IMA
7
ImageneBio Inc
IMA
$60.5M
| $13.9M | 4.22% |
176,837
+38,431
| +28% | +$2.76M |
|
8
Compass Therapeutics
CMPX
$454M
| $9M | 2.73% |
2,829,712
| – | – |
|
9
Larimar Therapeutics
LRMR
$421M
| $8.72M | 2.65% |
3,414,468
+668,203
| +24% | +$2.73M |
|
|
TSVT
10
DELISTED
2seventy bio
TSVT
| $8.62M | 2.62% |
852,007
-2,993
| -0.4% | -$31.7K |
|
|
INZY
11
DELISTED
Inozyme Pharma
INZY
| $6.66M | 2.02% |
1,195,027
-147,164
| -11% | -$870K |
|
|
OMGA
12
DELISTED
Omega Therapeutics, Inc. Common Stock
OMGA
| $5.91M | 1.79% |
1,055,882
| – | – |
|
|
13
Disc Medicine
IRON
$3.17B
| $5.56M | 1.69% |
+125,139
| New | +$4.44M |
|
|
14
Direxion Daily S&P Biotech Bear 3X ETF
LABD
$59.2M
| $4.67M | 1.42% |
+32,500
| New | +$4.85M |
|
|
ORTX
15
DELISTED
Orchard Therapeutics plc American Depositary Shares
ORTX
| $3.94M | 1.19% |
755,738
-30,000
| -4% | -$153K |
|
|
16
Ultragenyx Pharmaceutical
RARE
$2.59B
| $3.92M | 1.19% |
+85,000
| New | +$3.94M |
|
17
Black Diamond Therapeutics
BDTX
$130M
| $3.79M | 1.15% |
+750,000
| New | +$1.53M |
|
18
Rallybio
RLYB
$89M
| $3.07M | 0.93% |
67,847
-27,221
| -29% | -$1.33M |
|
19
Ovid Therapeutics
OVID
$572M
| $2.84M | 0.86% |
864,822
| – | – |
|
|
SYRS
20
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
| $2.42M | 0.73% |
767,445
| – | – |
|
21
Precision BioSciences
DTIL
$232M
| $843K | 0.26% |
53,452
-62,209
| -54% | -$1.42M |
|
|
HOOK
22
DELISTED
HOOKIPA Pharma
HOOK
| $694K | 0.21% |
+78,874
| New | +$876K |
|
|
LENZ
23
LENZ Therapeutics
LENZ
$151M
| $600K | 0.18% |
+32,991
| New | +$659K |
|
|
24
Corvus Pharmaceuticals
CRVS
$1.24B
| $458K | 0.14% |
200,000
-2,139,402
| -91% | -$4.44M |
|
|
25
CALL
Pliant Therapeutics
PLRX
$71.2M
| $162K | 0.05% |
+130,300
| New | +$3.08M |
|
Similar funds
SC
T
W
RBGI
TOGEPT
IAM
RCGI
AEPLI
CHI Advisors's Q2 2023 Portfolio in Review
As of Q2 2023, CHI Advisors held 32 positions worth $330M, down 13% from $377M the previous quarter. Its ten largest holdings account for 86% of the portfolio.
CHI Advisors withdrew a net $63.2M in Q2 2023, closing 6 positions and reducing 8 holdings. Its most notable exit was Prometheus Biosciences, Inc. Common Stock, an estimated $100M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 99% of assets, down from 100% a quarter earlier, followed by Miscellaneous.
Against the trend, CHI Advisors opened a new position in ACELYRIN worth $55.7M.
- CHI Advisors's largest Q2 2023 buy was ACELYRIN: 2,663,806 shares worth $55.7M.
- CHI Advisors added most to Keros Therapeutics in Q2 2023, an estimated $6.18M increase.
- CHI Advisors's biggest Q2 2023 reduction was VectivBio Holding AG Ordinary Shares, cutting an estimated $32.5M.
- CHI Advisors fully exited Prometheus Biosciences, Inc. Common Stock in Q2 2023, selling an estimated $100M.
- CHI Advisors's ten largest holdings make up 86% of its $330M portfolio in Q2 2023.
- CHI Advisors opened 8 new positions and closed 6 in Q2 2023.
- CHI Advisors's portfolio value fell 13% quarter-over-quarter to $330M.
Based on CHI Advisors's 13F filing for Q2 2023, filed 11 Aug 2023.